

613002-2026 - Konkurrensumsättning

Finland – Medicinsk utrustning, läkemedel och hygienartiklar – Large Cancer Panel Test

OJ S 172/2026 07/09/2026

Meddelande om upphandling eller koncession – standardsystem - Meddelande om ändring
Varor

1. Upphandlare

1.1. Upphandlare

Officiellt namn: HUS Group

E-postadress: kilpailutus.diagnostiikka@hus.fi

Köparens rättsliga status: Regional myndighet

Den upphandlande myndighetens verksamhet: Hälso- och sjukvård

2. Förfarande

2.1. Förfarande

Titel: Large Cancer Panel Test

Beskrivning: The HUS Group (also "the contracting entity", "the Client" or "HUS") requests tenders for a large cancer panel test for HUS Diagnostic Center. The procurement includes also data analysis software for reporting clinically significant variants, copy number alterations and gene fusions. The software can be offered by the same provider as the large cancer panel test or from a partner company (offer as a group or appeal to a subcontractor's resources), but it needs to be included in the same tender. The software will be procured for the entire lifecycle of the assay. The procurement consist of gene panels and reagents (also "products") and data analysis software (also "services", e.g. information system provided as Software as a Service). Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic genetic testing services to all patients at Helsinki and Uusimaa Hospital District. The laboratory operates as a health institution capable of validating in-house developed tests as required by the CE-IVD regulation. The services include analysis of both constitutional samples and malignancies. The laboratory provides sequencing services mainly using local sequencing capacity (Illumina NovaSeq 6000, NovaSeq X Plus, Ion GeneStudio S5 Prime equipment). The large cancer panel test is intended for detection of small nucleotide variants (SNVs), indels, gene fusions, copy number variations (CNVs), microsatellite instability (MSI), homologous recombination deficiency (HRD), and tumor mutation burden (TMB) relevant for the genetic profiling of solid tumor samples and/or hematological malignancies as well as plasma samples for cfDNA analysis. Sequencing of the samples is carried out using Illumina NovaSeq sequencers (Illumina NovaSeq 6000 and NovaSeq X Plus). The number of cancer panel tests performed annually is estimated to be between 2500-3000. The procurement is divided into LOT A and LOT B: LOT A - This lot includes gene panel solutions for in-house NGS testing of solid tumors and hematological malignancies, including library preparation reagents, target enrichment reagents defining the panel content, panel-specific reagents, data analysis software, and instructions for use. Sequencing reagents, flow cells, sequencing instruments, and testing services are not included in this procurement. - This test is based on analysis of total nucleic acids (RNA and/or DNA) extracted from paraffin embedded specimens and/or fresh-frozen specimens - This lot includes an option for special gene panel and reagents for salivary gland tumors with data analysis software - This lot includes an an option for a custom gene panel

and reagents with data analysis software - The HUS Group will decide separately on the use of the options LOT B Important Information Concerning Lot B of the Procurement Procedure The Contracting Authority has decided to discontinue Lot B of the procurement procedure. During the procurement procedure, it became apparent that substantial amendments are required to the subject matter of Lot B and the related procurement documents. As these amendments cannot be implemented through a corrigendum without jeopardising the equal and non-discriminatory treatment of tenderers, the Contracting Authority has decided to discontinue Lot B. Lot B will be re-tendered through a separate procurement procedure. A new contract notice and new procurement documents for Lot B will be published separately. Please note that LOT A is still continuing the tendering process. - This lot includes gene panel solutions for in-house NGS testing of cell-free DNA, including library preparation reagents, target enrichment reagents defining the panel content, panel-specific reagents, data analysis software, and instructions for use. Sequencing reagents, flow cells, sequencing instruments, and testing services are not included in this procurement - This test is based on analysis of cell-free DNA from plasma samples NOTE: For LOT A, the tenderer may offer a catalog panel, a combination of catalog panels, or a custom solution to meet the DNA and RNA requirements. For hematological malignancies, only a panel for DNA is requested. Panel for salivary gland tumors and custom panel are requested as an option. NOTE: FOR LOT A and LOT B, the tender needs to include all the reagents required to perform the assay, including library preparation reagents, indexing adapters and target enrichment reagents (or equivalent). Nucleic acid extraction reagents, library quantification reagents and sequencer reagents are excluded from the tender. The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices. The tenderer can submit a tender to either one or both of the LOTS A and LOT B. The tenderer can be awarded the contract to either one or both tendered lots. The contracting entity selects one (1) supplier for each lot and will enter into an agreement with the winning supplier. The estimated start for the contract period is autumn-winter 2026. The contracting entity receives a right to test use tendered panels and softwares after the deadline for receiving the tenders. The procurement volumes presented in the call for tenders are estimates, and the contract does not constitute a mandatory purchase obligation for the contracting entity or an exclusive right for the supplier to provide the product.

Förfarandets identifierare: 1781090e-38d5-4ca5-953e-9e6857485da0

Intern identifierare: HUS 324-2025

Typ av förfarande: Öppet

Förfarandet är påskyndat: nej

Förfarandets viktigaste kännetecken: The procurement shall comply with the Act on Public Procurement and Concession Contracts (1397/2016, referred to as the Public Procurement Act). The procurement value exceeds the EU threshold value. The procedure shall be an open procedure as defined in section 32 of the Public Procurement Act. PROCESSING OF TENDERS The procedure shall include the following phases: Contracting entity (HUS Group) 1. Opens the tenders 2. Verifies the suitability of the tenderer (ESPD form and Call for tenders) 3. Checks that the tenders conform to the invitation to tender 4. Compares the tenders (POSSIBLE TEST USE) 5. Requests and checks certificates and reports on the suitability of the winning tenderer(s) 6. Makes a procurement decision and communicates it to all the tenderers 7. Concludes an agreement with the selected tenderer(s) LANGUAGE OF THE TENDERING PROCEDURE The procurement documents are available in English. If a tenderer needs the documents in another language, the tenderer shall be responsible for translation and liable for the associated costs. Tenders must be prepared in English. PARALLEL TENDERS Parallel tenders are not permitted. PARTIAL TENDERS Partial tenders are permitted as follows: The tenderer may submit tender for one or two lots. Tenderer may be

awarded contracts for a maximum of two lots. **ALTERNATIVE TENDERS** Alternative tenders are not permitted. **PROCUREMENT VOLUMES** Any procurement volumes stated in the procurement documents are only estimates and therefore are not binding to the contracting entity. The contracting entity has no obligation to purchase any specific quantities. **DIVIDING INTO LOTS** The procurement agreement has been divided into lots. **RESERVATION FOR SUSPENDING THE PROCUREMENT** The contracting entity may suspend the procurement procedure in whole or in part for a real and justified reason (Article 125 of the Act on Public Procurement). **APPLICATION OF THE IPI REGULATION AND THE MEASURE** This procurement is subject to Regulation (EU) 2022/1031 of the European Parliament and of the Council (the International Procurement Instrument, IPI) as well as Commission Implementing Regulation (EU) 2025/1197. As required by the IPI measure, the contracting authority will exclude from the procurement procedure any tenderers originating from the People's Republic of China. In addition, the contracting authority will apply the obligations laid down in Article 8 of the IPI Regulation to the suppliers selected in the tendering procedure. See Annex "Main Agreement". If a tenderer offers products of Chinese origin, they will be treated in the procurement procedure in the same way as products originating from any other country. Chinese products are therefore not excluded from the procurement procedure. However, if products of Chinese origin are selected for the contract and, as a result, more than 50% of the contract value would consist of Chinese products (calculated from the total contract value, not the number of items), the tenderer must commit to the penalty fee described in Annex "Main Agreement", amounting to 10–30% of the value of the agreement. As a rule, products offered cannot be replaced after the procurement decision has been made. The underlying principle of public procurement procedures is the finality of the tender (Public Procurement Act, Section 74, and case law). In addition, Section 136 of the Public Procurement Act stipulates that contracts may not be substantially modified (replacing offered products with different ones would be regarded as a substantial modification). **ESTIMATED VALUE** The total estimated value of the procurement (VAT 0%) is approximately EUR 5 200 000. This is an estimate and the contracting entity does not commit neither to the stated euro amounts and nor the consumption figures indicated in the invitation to tender. The final order quantities may be higher or lower than stated.

2.1.1. Föremålet för upphandlingen

Kontraktets art: Varor

Huvudklassificering (cpv): 33000000 Medicinsk utrustning, läkemedel och hygienartiklar

Ytterligare klassificering (cpv): 48000000 Programvara och informationssystem, 72000000 IT-tjänster: konsultverksamhet, programvaruutveckling, Internet och stöd

2.1.2. Leveransplats

Del av land (NUTS): Helsinki-Uusimaa (FI1B1)

Land: Finland

2.1.4. Allmänna upplysningar

Rättslig grund:

Direktiv 2014/24/EU

2.1.5. Upphandlingsvillkor

Villkor för inlämning:

Högst antal delar som en anbudsgivare kan lämna anbud för: 2

Kontraktsvillkor:

Högst antal delar för vilka kontrakt kan tilldelas en anbudsgivare: 2

2.1.6. Uteslutningsgrunder

5. Del (anbudsområde)

5.1. Del (anbudsområde): LOT-0001

Titel: LOT A: Panels for Solid Tumors and Hematological Malignancies with Data Analysis Software

Beskrivning: The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices.

Intern identifierare: LOT A-0

5.1.1. Föremålet för upphandlingen

Kontraktets art: Varor

Huvudklassificering (cpv): 33000000 Medicinsk utrustning, läkemedel och hygienartiklar

Ytterligare klassificering (cpv): 48000000 Programvara och informationssystem, 72000000 IT-tjänster: konsultverksamhet, programvaruutveckling, Internet och stöd

5.1.2. Leveransplats

Del av land (NUTS): Helsinki-Uusimaa (FI1B1)

Land: Finland

5.1.3. Uppskattad löptid

Varaktighet: 36 Månader

5.1.6. Allmänna upplysningar

Reserverad upphandling:

Deltagande är inte reserverat.

Upphandlingsprojekt som inte finansieras med EU-medel

Upphandlingen omfattas av Världshandelsorganisationens avtal om offentlig upphandling, GPA : ja

Upphandlingen är också lämplig för små och medelstora företag: ja

5.1.9. Urvalskriterier

Källor till urvalskriterier: Upphandlingsdokument, Europeiskt enhetligt upphandlingsdokument

5.1.10. Tilldelningskriterier

Kriterium:

Typ: Pris

Beskrivning: Price

Kategori av tilldelningskriteriet vikt: Viktning (procentandel, exakt)

Sifferangivelse för tilldelningskriterium: 100

5.1.11. Upphandlingsdokument

Sista dag för att begära kompletterande information: 10/08/2026 09:00:00 (UTC+00:00)

Västeuropeisk tid

Adress till upphandlingsdokumenten: <https://tarjouspalvelu.fi/huslogistiikka?id=572070&tpk=f846dc2e-2626-4867-91e2-dff2eb40c0eb>

5.1.12. Upphandlingsvillkor

Villkor för inlämning:

Elektronisk inlämning: Krävs

Adress för inlämning: <https://tarjouspalvelu.fi/huslogistiikka?id=572070&tpk=f846dc2e-2626-4867-91e2-dff2eb40c0eb>

De språk som kan användas i anbud eller anbudsansökningarna: engelska

Elektronisk katalog: Ej tillåten

Anbudsgivare får lämna in fler än ett anbud: Ej tillåten

Tidsfrist för mottagande av anbud: 14/09/2026 09:00:00 (UTC+00:00) Västeuropeisk tid

Varaktighet under vilken anbudet måste förbli giltigt: 9 Månader

Information om offentlig anbudsöppning:

Öppningsdatum: 14/09/2026 09:01:00 (UTC+00:00) Västeuropeisk tid

Kontraktsvillkor:

Kontraktet måste genomföras inom ramen för program för skyddad anställning: Nej

Elektronisk fakturering: Krävs

Elektronisk beställning kommer att användas: ja

Elektronisk betalning kommer att användas: ja

5.1.15. Metoder

Ramavtal:

Upphandlingen avser inte ett ramavtal

Information om det dynamiska inköpssystemet:

Upphandlingen avser inte ett dynamiskt inköpssystem

5.1.16. Kompletterande information, medling och provning

Prövningsorganisation: Markkinaoikeus

Information om tidsfrist för provning: Unless otherwise provided below, an appeal shall be submitted in writing within 14 days of the date on which the candidate or tenderer received notice of the procurement decision together with instructions for appeal.

Organisation som ger mer information om prövningsförfaranden: Markkinaoikeus

5.1. Del (anbudsområde): LOT-0002

Titel: LOT B: CfDNA Panel Test with Data Analysis Software

Beskrivning: Important Information Concerning Lot B of the Procurement Procedure The Contracting Authority has decided to discontinue Lot B of the procurement procedure. During the procurement procedure, it became apparent that substantial amendments are required to the subject matter of Lot B and the related procurement documents. As these amendments cannot be implemented through a corrigendum without jeopardising the equal and non-discriminatory treatment of tenderers, the Contracting Authority has decided to discontinue Lot B. Lot B will be re-tendered through a separate procurement procedure. A new contract notice and new procurement documents for Lot B will be published separately. Please note that LOT A is still continuing the tendering process. The subject of the procurement and its requirements are described in more detail in the call for tender and its appendices.

Intern identifierare: LOT B-1

5.1.1. Föremålet för upphandlingen

Kontraktets art: Varor

Huvudklassificering (cpv): 33000000 Medicinsk utrustning, läkemedel och hygienartiklar

Ytterligare klassificering (cpv): 48000000 Programvara och informationssystem, 72000000 IT-tjänster: konsultverksamhet, programvaruutveckling, Internet och stöd

5.1.2. Leveransplats

Del av land (NUTS): Helsinki-Uusimaa (F11B1)

Land: Finland

5.1.3. Uppskattad löptid

Varaktighet: 36 Månader

5.1.6. Allmänna upplysningar

Reserverad upphandling:

Deltagande är inte reserverat.

Upphandlingsprojekt som inte finansieras med EU-medel

Upphandlingen omfattas av Världshandelsorganisationens avtal om offentlig upphandling, GPA
: ja

Upphandlingen är också lämplig för små och medelstora företag: ja

5.1.9. Urvalskriterier

Källor till urvalskriterier: Upphandlingsdokument, Europeiskt enhetligt upphandlingsdokument

5.1.10. Tilldelningskriterier

Kriterium:

Typ: Pris

Beskrivning: Price

Kategori av tilldelningskriteriet vikt: Viktning (procentandel, exakt)

Sifferangivelse för tilldelningskriterium: 100

5.1.11. Upphandlingsdokument

Sista dag för att begära kompletterande information: 10/08/2026 09:00:00 (UTC+00:00)

Västeuropeisk tid

Adress till upphandlingsdokumenten: <https://tarjouspalvelu.fi/huslogistiikka?id=572070&tpk=f846dc2e-2626-4867-91e2-dff2eb40c0eb>

5.1.12. Upphandlingsvillkor

Villkor för inlämning:

Elektronisk inlämning: Krävs

Adress för inlämning: <https://tarjouspalvelu.fi/huslogistiikka?id=572070&tpk=f846dc2e-2626-4867-91e2-dff2eb40c0eb>

De språk som kan användas i anbudet eller anbudsansökningarna: engelska

Elektronisk katalog: Ej tillåten

Anbudsgivare får lämna in fler än ett anbud: Ej tillåten

Tidsfrist för mottagande av anbud: 14/09/2026 09:00:00 (UTC+00:00) Västeuropeisk tid

Varaktighet under vilken anbudet måste förbli giltigt: 9 Månader

Information om offentlig anbudsöppning:

Öppningsdatum: 14/09/2026 09:01:00 (UTC+00:00) Västeuropeisk tid

Kontraktsvillkor:

Kontraktet måste genomföras inom ramen för program för skyddad anställning: Nej

Elektronisk fakturering: Krävs

Elektronisk beställning kommer att användas: ja

Elektronisk betalning kommer att användas: ja

5.1.15. Metoder

Ramavtal:

Upphandlingen avser inte ett ramavtal

Information om det dynamiska inköpssystemet:

Upphandlingen avser inte ett dynamiskt inköpssystem

5.1.16. Kompletterande information, medling och prövning

Prövningsorganisation: Markkinaoikeus

Information om tidsfrist för prövning: Unless otherwise provided below, an appeal shall be submitted in writing within 14 days of the date on which the candidate or tenderer received notice of the procurement decision together with instructions for appeal.

Organisation som ger mer information om prövningsförfaranden: Markkinaoikeus

8. Organisationer

8.1. ORG-0001

Officiellt namn: Markkinaoikeus

Registreringsnummer: 3006157-6

Postadress: Radanrakentajantie 5

Ort: Helsinki

Postnummer: 00520

Del av land (NUTS): Helsinki-Uusimaa (FI1B1)

Land: Finland

E-postadress: markkinaoikeus@oikeus.fi

Tfn: +358 295643300

Webbadress: <http://www.oikeus.fi/markkinaoikeus>

Den här organisationens roller:

Prövningsorganisation

Organisation som ger mer information om prövningsförfaranden

8.1. ORG-0002

Officiellt namn: HUS Group

Registreringsnummer: 1567535-0

Postadress: Uutistie 5 (PO Box 441, 00029 HUS)

Ort: Vantaa

Postnummer: 01770

Del av land (NUTS): Helsinki-Uusimaa (FI1B1)

Land: Finland

Kontaktpunkt: HUS Group

E-postadress: kilpailutus.diagnostiikka@hus.fi

Tfn: +358 94711

Webbadress: <http://www.hus.fi>

Den här organisationens roller:

Upphandlare

8.1. ORG-0003

Officiellt namn: Hansel Oy (Hilma)

Registreringsnummer: FI09880841

Postadress: Mannerheiminaukio 1a

Ort: Helsinki

Postnummer: 00100

Del av land (NUTS): Helsinki-Uusimaa (FI1B1)

Land: Finland

Kontaktpunkt: eSender

E-postadress: tekninen@hankintailmoitukset.fi

Tfn: 029 55 636 30

Webbadress: <http://hankintailmoitukset.fi>

10. Ändring

Version av det föregående meddelandet som ska ändras

:

e2b9b446-1635-46cc-9963-c79108a7dbd3-01

Huvudskälet till ändringen

:

Rättelse av utgivaren

Beskrivning

:

The incorrect date in the appendix has been corrected The Contracting Authority has decided to discontinue Lot B of the procurement procedure. During the procurement procedure, it became apparent that substantial amendments are required to the subject matter of Lot B and the related procurement documents. As these amendments cannot be implemented through a corrigendum without jeopardising the equal and non-discriminatory treatment of tenderers, the Contracting Authority has decided to discontinue Lot B. Lot B will be re-tendered through a separate procurement procedure. A new contract notice and new procurement documents for Lot B will be published separately. Please note that LOT A is still continuing the tendering process.

10.1. Ändring

Identifierare för avsnitt: PROCEDURE

10.1. Ändring

Identifierare för avsnitt: LOT-0002

Information om meddelandet

Identifierare/version för meddelandet: 9d48b8da-f224-4d69-9539-d48d7bfa8aac - 01

Formulärtyp: Konkurrensutsättning

Meddelandetyp: Meddelande om upphandling eller koncession – standardsystem

Meddelandets undertyp: 16

Avsändningsdatum för meddelandet: 04/09/2026 08:49:13 (UTC+00:00) Västeuropeisk tid

Datum för avsändning av meddelandet (eSender): 04/09/2026 08:49:15 (UTC+00:00)

Västeuropeisk tid

Språk som det här meddelandet finns officiellt tillgängligt på: engelska

Meddelandets publiceringsnummer: 613002-2026

EUT S-nummer: 172/2026

Publiceringsdatum: 07/09/2026